TMB and Neoantigen Congress

When

2019年10月10-11日
Registration from 8am

Where

英國,倫敦
London Heathrow Marriott Hotel

TMB and Neoantigen Congress
-TMB、新生抗原學會-
日期:2019年10月10-11日
地點:英國,倫敦,London Heathrow Marriott Hotel
Choose your language
Chinese
Japanese
Korean
English

TMB and Neoantigen Congress

在新標的、預測生物標記、個別化醫療領域的進步

此學會透過預測生物標記以及新生抗原的創新研究,聚焦於以下課題:研究者致力於如何將成功可能性高的療法與患者連結。在會議期間,也包括關於腫瘤突變負荷量(TMB)的最新研究,在免疫療法藥物的治療效果確認使用TMB的可能性、關於其他預測生物標記之開發等主題之會議,還有探討新生抗原成為精密醫療新標的可能性之會議。

“I met leading companies/biomarker developers at one place sharing cutting edge technologies”.

“interesting mixture of topics; possibility to discuss with the attendees”

“Learned a lot from some of the talks”

此學會是關於癌症免疫療法的研究及技術為主題的系列活動之一。申請參加此學會的來場者,能夠在5個學會中聆聽100個以上的演講,還能夠與跨領域的人們認識,擴大人脈,吸收新知。

可參加同時舉辦的學會

 

2019年10月10日(四) – 關於TMB與新生抗原研究之運用


基調演講: 癌症免疫療法藥物開發的ctDNA生物標記:可能性及課題
RAJIV RAJA, Director, Oncology Translational Medicine, AstraZeneca, USA
Circulating tumor DNA (ctDNA) derived from plasma offer significant promise as a tool for assessing tumor burden and antitumor response. Changes in levels of ctDNA from baseline have been shown to correlate with response to some immunotherapies. Recent studies have also shown that ctDNA could be used to measure tumor mutation burden (TMB) which could be a potential predictive biomarker for response to immunotherapies. ctDNA results from immunotherapy studies will be discussed, and opportunities and challenges with ctDNA analysis will be discussed.

基調演講: 減輕毒性風險&對患者的利益最大化
CHRISTOPHE LE TOURNEAU, Head, Department of Drug Development and Innovation (D3i), Institut Curie, France
Optimising patients benefit whilst reducing toxicity risk is the ultimate goal of precision medicine in oncology. While precision medicine has always been a reality in medicine with treatments adjusted based on the clinical condition of patients, the term “precision medicine” has arisen with the advent of molecularly targeted therapies that were developed based on biomarkers that were mostly DNA alterations. Precision medicine does not apply only for molecularly targeted therapies but also for immunotherapeutics especially immune checkpoint inhibitors, for which predictive biomarkers of efficacy have been identified at the genomic level.

PRESENTATION


Morning Refreshments / Poster Presentations


Will whole genome sequencing of fresh frozen tumour material become the assay of choice for cancer molecular diagnostics?
WILL SPOONER, Commercial Programme Delivery Lead, Genomics England, UK
At the start of the 100,000 Genomes Project it became clear that formalin fixed paraffin embedded tumour material was not suitable for whole genome sequencing. An alternative “WGS friendly” fresh frozen protocol (FF-WGS) was developed and implemented as a clinical pathway in the NHS. This protocol has been used to generate a dataset of linked genome-to-health data from 15,000 cancer cases. Analysis of the dataset suggests that our FF-WGS assay that has the potential to more reliably and accurately measure cancer markers such as TMB. This talk presents these data and considers the challenges of introducing FF-WGS-based tests into clinical
trials and practice. Finally, we speculate on the mining of large FF-WGS datasets to identify the next generation of cancer biomarkers.

TMB and MSI in clinical application using comprehensive tumor profiling
MARTIN ZOCHE, Director Molecular Tumor Profiling, University Hospital Zurich, Switzerland
• Comprehensive molecular tumor profiling is standard at the University Hospital Zurich is as a diagnostic standard
procedure for all tumor patients.
• Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI) analysis are integrated in the molecular report
and discussed.
• Patient cases will illustrate the advantages for the tumor patients

PRESENTATION
Oncoimmunity


Lunch


ATLAS™ - A Critical Tool in Finding True Neoantigens
PAMELA CARROLL, Senior Vice President, Scientific Strategy, Genocea Biosciences, USA
• ATLAS™ is a powerful tool that screens all candidate neoantigens for pre-existing patient-specific CD4 or CD8 responses
in an HLA agnostic assessment.
• ATLAS also identifies inhibitory peptides that may suppress tumor immunity, accelerate tumor progression and mediate
patient response to immune checkpoint blockade therapies.
• ATLAS-selected neoantigens are the basis of a vaccine, GEN-009, currently being evaluated in Phase 1/2a clinical trials. Also, ATLAS is
being applied to a personalized non-engineered T cell therapy program that targets multiple neoantigens.

Combined treatment with checkpoint blockade and Adenovirus vaccine targeting multiple neoantigens eradicates large tumors in mice
ELISA SCARSELLI, CSO, Nouscom, Italy
• Non-human Great Ape Adenoviruses (GAd) are potent vaccine vectors able to encode many neoantigens
• Vaccination synergizes with α-PD-1 in mice bearing large established tumours
• Combined treatment results in diversification of the intra-tumor T cell repertoire

Considerations and experiences from taking a fully personalized targeted cancer neoantigen DNA vaccine into the clinic
AGNETE FREDRIKSEN, President and CSO, Vaccibody, Norway
• What is the rationale to pursue development of individualized cancer vaccines and make it a viable product for the market?
• How does the vaccine format affect the immunogenicity profile of individual neoepitopes?
• Update from DIRECT-01, a clinical trial testing private cancer neoantigen based vaccines in patients with advanced cancer


Afternoon Refreshments / Poster Presentations


Tailor-made immunotherapies: Integrating non-mutated and neoantigens into highly personalized
immunotherapy approaches
SARAH MISSEL, Director, Translational Development, R&D Strategy and Communications, Immatics, Germany
• The role of neoantigens and non-mutated antigens in tumors with low mutational burden
• GAPVAC – Actively Personalized Vaccination in newly diagnosed glioblastoma patients – results of the clinical study
GAPVAC-101
• Highly personalized Adoptive Cellular Therapy

Viral-based vaccine for cancer neoantigen vaccination
KAIDRE BENDJAMA, Project Leader, Personalized Cancer Vaccination, Transgene, France
Viral vectors constitute a promising modality for cancer vaccines. Viral vectors were used successfully to generate cancer vaccines in a number of indications using Tumor associated antigen as targets to induce a specific T cell response. The presentation will provide an overview on how Transgene uses the MVA viral strain to meet specific challenges related neoantigen vaccination from sequencing to neoepitope selection to manufacturing and QC to deliver a clinical grade product and on how these vaccines will be translated into the clinic in indications of high medical needs.


Networking Drinks Reception


染色體碎裂(Chromothripsis)有可能提高新生抗原負荷
GEORGE VASMATZIS, Co-director of the Biomarker Discovery Program, Associate Professor, Department of Molecular Medicine, Mayo Clinic, USA
• We observed that inter- or intrachromosomal rearrangements are present in many cancers frequently in a pattern of chromoanagenesis such as chromoplexy or chromothripsis.
• Transcription of rearrangement-related junctions was predicted to result in many potential neoantigens, some of which were proven to bind patient-specific major histocompatibility complex molecules and to expand intratumoral T cell clones.
• Subsets of prostate, lung, and breast, cancers as well as some sarcomas are among those that could present neoantigens that derive from complex rearrangements

PepPipe - an immunomics workflow elucidating antigenic peptide biomarker signatures for minimal invasive diagnostics
ANDREAS WEINHAUSEL, Thematic Coordinator, Molecular Diagnostics, AIT - Austrian Institute of Technology, Austria
Autoantibody & antibody-profiles are biologically meaningful and suitable as early and minimal invasive markers using 10µl of plasma or serum. Since the immune system plays a major role in many diseases, sero-testing and immunomics analysis has a broad area of application and a high potential for diagnostics of autoimmune, cancerous, cardiologic, neurodegenerative and systemic diseases, as well as assisting biotech and pharma for selecting therapeutic targets or study off-target reactivities. PepPipe provides an entire workflow of optimised and QM qualified methods to define antigenic proteins and peptides for
serological analysis. We have developed a broad variety of assays with different multiplexing capacities to provide the entire workflow “from screening to validation” and “from proteins to peptides” to define and analyse antigenic proteins and peptides supporting clinical and therapeutic developments, and improving robust minimal invasive diagnostics.


Morning Refreshments / Poster Presentations


The promise and challenge of TMB in the clinics for immunotherapy
EUN-ANG RAIBER-MOREAU, Associate Principal Scientist, AstraZeneca, UK
Tumour mutational burden (TMB) is emerging as an important biomarker that hold promise to aid in the selection of patients for immunotherapy. TMB is defined as the total number of mutations per megabase within the coding area of the genome. TMB was initially assessed using whole exome sequencing but new studies have shown that targeted NGS panels can be used for TMB calling reducing down the costs and turn-around time. In this presentation, we will discuss the challenges of implementing TMB testing into routine clinical settings with a focus on the importance of TMB standardization and blood versus tissue TMB testing

Developing proteogenomcis platforms in cancers of high unmet clinical need
TEDD HUPP, Chair of Cancer Research, University of Edinburgh, UK
Proteogenomics platforms are being developed that can reveal the expressed cancer genome as we evolve towards personalized therapies. Our network aims to (i) define comprehensively the biological sources of cancer neoantigens; (ii) evolve algorithmic strategies for mass-spectrometry based mutation identification; (iii) identify novel genes that regulate MHC Class I production in cancers; and (vi) apply this knowledge on the mutant peptidome to form therapeutic options in cancers of high unmet clinical need.


Lunch


Using Artificial Intelligence to accelerate Immunotherapy
JENS KRINGELUM, Director, Genomic Immuno Oncology, Evaxion Biotech, Denmark
• What is AI and how can it be used to predict immune responses in patients
• The use of AI driven prediction tools for design of novel immunotherapies
• Opportunities and challenges in using AI technology to drive truly personalised treatments

Application of in vitro tools that improve selection of (neo)epitopes and characterize T cell responses
ASTRID VISSER, Business Development Manager, Sanquin, The Netherlands
• Measured peptide-MHC binding / stability that improves (neo)epitope selection
• Multi-parameter FACS that efficiently detects and characterizes multiple pre-existing and induced epitope-specific
T-cell responses
• Efficient peptide-MHC-exchange based assay that allows cross-reactivity and safety studies for peptide-MHCantibodies and TCR mimics

Personalized NeoTCR-T Cell Therapies for Solid Tumors
ALEX FRANZUSOFF, CEO, PACT Pharma
PACT Pharma is developing personalized tumor-mutation (neoantigen or neoepitope) targeted T cells tailored for each patient. Using (non-viral) precision genome engineering, a fresh collection of autologous patient T cells are reprogrammed to produce ‘native’ autologous tumor mutation-targeted T cells (neoTCR-T cells) for administration as a ‘living drug’ back to the patient. In this talk, I will discuss PACT’s development of neoTCR-T cell products exclusively for each patient, as well as the remarkable landscape of neoE-specific T cells (direct capture) in blood or TILs of patients, as well as the evolution of neoE-T cell responses in I-O trials. These developments represent a new frontier for programming fresh, autologous human T cells with ‘new tricks’ to personalize the treatment of patients with the spectrum of solid tumors.

Profiling of neo-antigens presented by cancer cells facilitate patient stratification and development of potent antitumor therapies
TIM FUGMANN, Senior Scientist, Max Delbruck Center and Senior Scientific Advisor, Alithea Bio, Switzerland
• Aberrantly expressed transcripts lead to presentation of neo antigens on cancer cells
• Aberrant expression is a common event leading to antigens shared between multiple tumors
• Such neo antigens can be targeted by adoptive T cell therapies


Chair’s Closing Remarks / Conference Close


* 活動內容有可能不事先告知作更動及調整。

 

議程

本學會有超過350位專家齊聚一堂,對於如何將患者與成功可能性較高的治療法做出連結進行討論,對於致力研究開發因應個別患者狀況提高治療效果技術的學者來說,請千萬不要錯過本活動。

Download the Agenda (PDF)

演講者

贊助商

所有贊助商名單

地點

London Heathrow Marriott Hotel

London Heathrow Marriott900

Bath Road, Harlington, Hayes, Middlesex, UB3 5AN

海報發表

海報發表不僅在休息時間進行,也會與分科會討論同時進行。所有藥廠或研究機構的研究人員所製作的海報,都必須在獲得學會事務局許可後張貼於會場內指定區域。

此外,學會閉幕後,將發給所有出席者匯集海報發表大綱的電子書,亦可將海報以.pdf形式的檔案公開(僅限意者)。

海報發表對於尋求出資和雇用機會的人,以及希望在志同道合、研究同一題目的研究者團體中發表成果的人來說,是能夠在會場內廣受矚目的珍貴機會。

必須報名參加本年會方可進行海報發表。張貼海報的空間有限,將依報名順序接受通過審查者張貼海報,故建議盡早申請。

企業發表海報需要支付100英鎊管理費用。費用包括區域保留費用與展示板費用以及各種其他手續費。研究機構與非營利組織可免費發表。

海報發表報名辦法

請填寫專用表格(點擊下列連結下載)於2019年9月20日以前繳交。若於截止日期前額滿將提早截止報名,敬請儘早申請。詳情歡迎與我們聯繫。

學會的贊助商

贊助商募集

藉由成為本年會的贊助商或參展者,可在融洽的氣氛中,與各組織的代表於各種正式、非正式的場合進行會談,建立合作關係的機會。

本年會準備了各種贊助方案,豐富的選項可配合您的業務需求自由搭配,以獲取最大額度的投資報酬。

欲採其他方式贊助本學會者,或考慮進行方案規畫者,歡迎隨時與本會洽詢。本會將提出合乎個別需求的服務建議。

可事先預約的20分鐘個別會談時段

贊助商與參展者可以事先預約在主要研討會的分科會會議中排定的20分鐘個別會談時段,與希望的對象見面。會期中,Global Engage團隊會常駐會場,協助會談按時進行。

年會前後的研討會

可在年會前後以對特定主題感到興趣者為對象,舉辦為期半天或全天的工作坊活動。Global Engage將協助宣傳以確保工作坊達到足夠的出席人數。

年會開幕前的行銷與宣傳

利用Global Engage的資料庫展開行銷活動,透過海報張貼、休息與午餐會、酒會、贊助海報發表等提高品牌知名度。另備有追加項目可將貴公司的logo印製在發放給與會者的名牌吊繩與年會資料包上。

參展

會議期間設有專用的展示區域,可向所有的與會者展示您的技術與產品。展示區域將設於休息及午餐會,以及第一天晚上的歡迎酒會的舉辦場所。

演講

發言的型態

  • 30分鐘演講
  • 在30分鐘專題討論中擔任主持人或討論人員
  • 在年會議程中舉行一小時的研討會
募集贊助商

歡迎來信或來電與日商環球訊息有限公司台灣分公司聯繫。

包括簽證等各種海關所需文件,以及展示用品的通關手續皆由展商企業各自負責。

展示相關的安排(企業介紹、公司商標、提供與會者目錄中的展商資訊登錄、展示空間的裝潢、用品訂購、展示用品的擺設搬運、展示空間的文件申請、保險等)請直接與主辦方連繫。

旅遊相關疑問(住宿、機票)、當地翻譯人員、飛行與意外保險等問題,將有另外的專門業者分別提供服務。

TMB & Neoantigen Congress贊助方案詳情歡迎隨時來信或來電詢問

關於出席與各種方案詳情歡迎隨時詢問。將有專員提供進一步資訊。

媒體合作夥伴

  • 247 Updates
  • Bentham Science
  • Biocompare
  • Biotechgate
  • EIN Presswire
  • Global Information
  • Pharma Journalist
  • PharmaVOICE
  • SciDoc Publishers
  • Pharmaceutical Tech
 
免費電子郵件通知服務